Previous 10 | Next 10 |
2024-01-19 09:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-18 08:36:41 ET More on Lipocine Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine For further details see: Lipocine licenses Tlando testosterone therapy to Verity Pharma
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis PR Newswire VYVDURA® provides patients with option for self-administration SAN DI...
2024-01-18 07:00:29 ET More on Argenx SE, Bayer, etc. Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) argenx: Back To Earth After 2 Clinical Tria...
2024-01-17 08:53:24 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...
2024-01-16 12:40:46 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PR Newswire SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therape...
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types PR Newswire Reduces treatment time by approximately 80% compared to standard ...
Halozyme to Host Investor Business Forum and Long-Term Outlook Call PR Newswire SAN DIEGO , Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call ...
2024-01-08 17:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 21% YOY to $196 million ; Net Income of $77 million ; Adjusted EBITDA of $116 million ; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...